

cannasouth market announcement

For Public Release

NZX Limited Wellington

14 February 2024

Cannasouth Announces Resignation of RestoreMe Clinic Ltd CEO

Cannasouth Limited (NZX: CBD) announces the resignation of Mr. Brendon Ogilvy, CEO of subsidiary company RestoreMe, effective 1 March 2024.

Mr. Mark Lucas, CEO, thanks Mr. Ogilvy for his service and acknowledges the significant contribution to the affairs of Egalis Group during his 5-year term.

"I thank Brendon for his contributions to the Company, in particular the launch of online clinic RestoreMe in November 2022, and wish him well for his next career challenge."

Mr. Lucas will assume executive management of RestoreMe.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster

CFO / Company Secretary Email: <u>colin.foster@cannasouth.co.nz</u> Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Eqalis Group New Zealand Ltd.

For video footage, photos and logos please visit: https://www.cannasouth.co.nz/about/media/